Article
Moderna/Merck begins late-stage study of skin cancer vaccine combination
Rating:
0.0
Views:
57
Likes:
1
Library:
1
Moderna and its partner Merck said on Wednesday that they had begun enrolling patients in a late-stage study testing their personalized mRNA-based skin cancer vaccine in combination with the immunotherapy Keytruda.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value